Lipoxins, resolvins and protectins: New leads for the treatment of asthma

Expert Opinion on Drug Discovery

Volumn 3, Issue 10, 2008, Pages 1209-1222

  Haworth, Oliver ^a   Levy, Bruce D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Analogues; Asthma; Inflammation; Lipoxins; Mediators; Resolution

Indexed keywords

15 EPI 16 (4 FLUOROPHENOXY)LIPOXIN A; 15 HYDROXYICOSATETRAENOIC ACID; 3 OXA LIPOXIN A DERIVATIVE; ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; AROMATIC HYDROCARBON RECEPTOR; CD59 ANTIGEN; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOXIN; LIPOXIN A; LIPOXIN RECEPTOR; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OMEGA 3 FATTY ACID; PEPTIDOLEUKOTRIENE; PROTECTIN D1; RESOLVIN; RESOLVIN D1; RESOLVIN E1; RESPIRATORY TRACT AGENT; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; ZK 142; ZK 994;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; CONTACT ALLERGY; DENDRITIC CELL; DRUG ABSORPTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENDOTHELIUM CELL; EOSINOPHIL; EPITHELIUM CELL; HOST RESISTANCE; HUMAN; MACROPHAGE; NATURAL KILLER CELL; NEUROMODULATION; NONHUMAN; PERITONITIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; TARGET CELL; UNSPECIFIED SIDE EFFECT;

EID: 55049131701     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.10.1209     Document Type: Review

References (95)

1. Vandenplas O, Toren K, Blanc PD. Health and socioeconomic impact of work-related asthma. Eur Respir J 2003;22(4):689-97
2. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344(5):350-62
3. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2006;21(2):325-32
4. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008;8(3):218-30
5. Levy BD, Bonnans C, Silverman ES, et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005;172(7):824-30
6. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Ann Rev Immunol 2007;25:101-37
7. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984;81(17):5335-9
8. Meini S, Evangelista S, Geppetti P, et al. Pharmacologic and neurochemical evidence for the activation of capsaicin-sensitive sensory nerves by lipoxin A4 in guinea pig bronchus. Am Rev Respir Dis 1992;146(4):930-4
9. Svensson CI, Zattoni M, Serhan CN. Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J Exp Med 2007;204(2):245-52
10. Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J Exp Med 1990;172(5):1451-7
11. Levy BD, Romano M, Chapman HA, et al. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-transeicosatetraenoic acid and lipoxins. J Clin Invest 1993;92(3):1572-9
12. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995;92(21):9475-9
13. Claria J, Lee MH, Serhan CN. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996;2(5):583-96
14. Birnbaum Y, Ye Y, Lin Y, et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006;114(9):929-35
15. Serhan CN, Fiore S, Brezinski DA, Lynch S. Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. Biochemistry 1993;32(25):6313-9
16. Serhan CN, Maddox JF, Petasis NA, et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995;34(44):14609-15
17. Chiang N, Serhan CN, Dahlen SE, et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006;58(3):463-87
18. Chiang N, Fierro IM, Gronert K, Serhan CN. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med 2000;191(7):1197-208
19. Fiore S, Maddox JF, Perez HD, Serhan CN. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med 1994;180(1):253-60
20. Arita M, Bianchini F, Aliberti J, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005;201(5):713-22
21. Levy BD, Fokin W, Clark JM, et al. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4. FASEB J 1999;13(8):903-11
22. Ohira T, Bannenberg G, Arita M, et al. A stable aspirin-triggered lipoxin A4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils. J Immunol 2004;173(3):2091-8
23. Gronert K, Gewirtz A. Madara JL, Serhan CN. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis Factor alpha-induced IL-8 release. J Exp Med 1998;187(8):1285-94
24. Levy BD, De Sanctis GT, Devchand PR, et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 2002;8(9):1018-23
25. Devchand PR, Arita M, Hong S, et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J 2003;17(6):652-9
26. Schaldach CM, Riby J, Bjeldanes LF. Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 1999;38(23):7594-600
27. Machado FS, Johndrow JE, Esper L, et al. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med 2006;12(3):330-4
28. Aliberti J, Hieny S, Reis e Sousa C, et al. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat Immunol 2002;3(1):76-82
29. Machado FS, Esper L, Dias A, et al. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. J Exp Med 2008;205(5):1077-86
30. Gronert K, Martinsson-Niskanen T, Ravasi S, et al. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol 2001;158(1):3-9
31. Lee TH, Crea AE, Gant V, et al. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis 1990;141(6):1453-8
32. Dahlen SE, Franzen L, Raud J, et al. Actions of lipoxin A4 and related compounds in smooth muscle preparations and on the microcirculation in vivo. Adv Exp Med Biol 1988;229:107-30
33. Christie PE, Spur BW, Lee TH. The effects of lipoxin A4 on airway responses in asthmatic subjects. Am Rev Respir Dis 1992;145(6):12814
34. Sanak M, Levy BD, Clish CB, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000;16(1):44-9
35. Celik GE, Erkekol FO, Misirligil Z, Melli M. Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin Exp Allergy 2007;37(10):1494-501
36. Planaguma A, Kazani S, Marigowda G, et al. Airway LXA4 generation and LXA4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008: 200801-061OC [pii] 10.1164/rccm.200801-061OC
37. Vachier I, Bonnans C, Chavis C, et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005;115(1):55-60
38. Tahan F, Saraymen R, Gumus H. The role of lipoxin A4 in exercise-induced bronchoconstriction in asthma. J Asthma 2008;45(2):1614
39. Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004;5(4):388-92
40. Clish CB, O'Brien JA. Gronert K, et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci USA 1999;96(14):8247-52
41. Levy BD, Lukacs NW, Berlin AA, et al. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J 2007;21(14):3877-84
42. Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001;2(7):612-9
43. Schwartz J, Weiss ST. The relationship of dietary fish intake to level of pulmonary function in the first National Health and Nutrition Survey (NHANES I). Eur Respir J 1994;7(10):1821-4
44. Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 1929;8:345-67
45. Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192(8):1197-204
46. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196(8):1025-37
47. Hudert CA, Weylandt KH, Lu Y, et al. Thansgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006;103(30):11276-81
48. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007;13(7):868-73
49. Hong S, Gronert K, Devchand PR, et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003;278(17):14677-87
50. Serhan CN, Gotlinger K, Hong S, et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 2006;176(3):1848-59
51. Duffield JS, Hong S, Vaidya VS, et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 2006;177(9):5902-11
52. Sun YP, Oh SF, Uddin J, et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 2007;282(13):9323-34
53. Haworth O, Cernadas M, Yang R, et al. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008;9(8):873-9
54. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198(7):977-85
55. Cash JL, Hart R, Russ A. et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008;205(4):767-75
56. Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007;178(6):3912-7
57. Lukiw WJ, Cui JG, Marcheselli VI, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005;115(10):2774-83
58. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004;101(22):8491-6
59. Levy BD, Kohli P, Gotlinger K, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007;178(1):496-502
60. Bannenberg GL, Chiang N, Ariel A, et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005;174(7):4345-55
61. Canny G, Levy O, Furuta GT, et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA 2002;99(6):3902-7
62. Hasturk H, Kantarci A, Goguet-Surmenian E, et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 2007;179(10):7021-9
63. Hasturk H, Kantard A, Ohira T, et al. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 2006;20(2):401-3
64. Serhan CN, Jain A, Marleau S, et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003;171(12):6856-65
65. Aliberti J, Serhan C, Sher A. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and inummopathology in Toxoplasma gondii infection. J Exp Med 2002;196(9):1253-62
66. Haas-Stapleton EJ, Lu Y, Hong S, et al. Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS One 2007;202):e1316
67. Vance RE, Hong S, Gronert K, et al. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci USA 2004;101(7):2135-9
68. Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets 2006;5(2):91-106
69. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004;3(10):831-44
70. Guilford WJ, Parkinson JF. Second-generation beta-oxidation resistant 3-oxa-lipoxin A4 analogs. Prostaglandins Leukot Essent Fatty Acids 2005;73(3-4):245-50
71. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immumol 2008;8(3):183-92
72. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol 2002;64(11):1549-57
73. Smith LJ. A risk-benefit assessment of antileukotrienes in asthma. Drug Saf 1998;19(3):205-18
74. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D 1 activate inflammation-resolution programmes. Nature 2007;447(7146):869-74
75. Rao NL, Dunford PJ, Xue Y, et al. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther 2007;321(3):1154-60
76. Colgan SP, Serhan CN, Parkos CA, et al. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest 1993;92(1):75-82
77. Papayianni A, Serhan CN, Brady HR. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol 1996;156(6):2264-72
78. Soyombo O, Spur BW, Lee TH. Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Allergy 1994;49(4):230-4
79. Bandeira-Melo C, Bozza PT, Diaz BL, et al. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking. J Immunol 2000;164(5):2267-71
80. Ariel A, Chiang N, Arita M, et al. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol 2003;170(12):6266-72
81. Ramstedt U, Serhan CN, Nicolaou KC, et al. Lipoxin A-induced inhibition of human natural killer cell cytotoxicity: studies on stereospecificity of inhibition and mode of action. J Immunol 1987;138(1):266-70
82. Godson C, Mitchell S, Harvey K, et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000;164(4):1663-7
83. Brezinski ME, Gimbrone MA Jr, Nicolaou KC, Serhan CN. Lipoxins stimulate prostacyclin generation by human endothelial cells. FEBS Lett 1989;245(1-2):167-72
84. Bonnans C, Fukunaga K, Levy MA. Levy BD. Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. Am J Pathol 2006;168(4):1064-72
85. Campbell EL, Louis NA, Tomassetti SE, et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J 2007;21(12):3162-70
86. Ariel A, Fredman G, Sun YP, et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 2006;7(11):1209-16
87. Ariel A, Li PL, Wang W, et al. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem 2005;280(52):43079-86
88. Jozsef L, Zouki C, Petasis NA, et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocyces. Proc Natl Acad Sci USA 2002;99(20):13266-71
89. Machado FS, Esper L, Dias A, et al. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. J Exp Med 2008;205(5):1077-86
90. Fiorucci S, Wallace JL, Mencarelli A. et al. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci USA 2004;101(44):15736-41
91. Chiang N, Gronert K, Clish CB, et al. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999;104(3):309-16
92. Fierro IM, Kutok JL, Serhan CN. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 2002;300(2):385-92
93. Gronert K, Maheshwari N, Khan N, et al. A role for the mouse 12/ 15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 2005;280(15):15267-78
94. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005;102(21):7671-6
95. Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis 2007;13(6):797-9